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Summary 
Background  According to published data, the ability to prevent various hypertension related 
events differs between the various anti-hypertensive drug groups.  Although absolute drug effects 
with similar drugs also differ among the various studies, relative drug effects could be considered 
constant.  We therefore explored the possibility of drawing statistically valid conclusions about 
the differences between various drug groups by doing an overview of published data.  
Methods  We performed a meta-analysis using a Bayesian fixed effect model in which we 
brought together 27 published studies. We chose to always relate the drug effects to the number 
of events observed with placebo drugs. We therefore obtained results both from studies reporting 
the effects of the newer drugs when tested against	
 -blockers, and from studies in 
	
 -blockers had been tested against placebo. We constructed the posterior 
probability distributions of the relative effects of ACE-inhibitors versus calcium antagonists with 
three different endpoints: stroke, coronary disease and heart failure. We then calculated point 
estimates of effects with 95% credibility intervals. As an intermediate step in this procedure we 
obtained similar information about the effects of the three groups of active drugs, ACE-inhibitors, 



		
	 -blockers, tested against placebo.  
Findings  ACE-inhibitors and calcium antagonists have an almost identical ability to prevent 
stroke in hypertensive individuals with a risk ratio (RR) of 1.04.  On the other hand, calcium 
antagonists reduce coronary disease by only 9% relative to placebo. When ACE-inhibitors and 
calcium antagonists are compared by the Bayesian method, the outcome is a 14% difference in 
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favour of the ACE-inhibitors to prevent coronary disease, with a credibility interval reaching 
identity. Nor do calcium antagonists do as well as diur	 -blockers in this respect, RR = 
1.11 with 95% credibility interval 1.01 to 1.22. All the tested drug groups have a profound 
preventive effect on the occurrence of heart failure when given to hypertensive patients, showing 
reductions of 44% to 56%. When ACE-inhibitors are compared with calcium antagonists the risk 
ratio is 0.79, with a credibility interval 0.65 to 0.95.  
Interpretation The conclusion of our analysis is a statistically significant difference between 
ACE-inhibitors and calcium antagonists in respect of effects on coronary disease and heart failure 
when treating hypertensive individuals, ACE-inhibitors being more efficacious. The difference is 
modest and both drug groups are acceptable as first line treatments together with diuretics a -
blockers. There are no differences in the effect on stroke. 
 
 
 
 
Introduction 
A series of publications between 1974 and 1994 established a positive effect of drug treatment on 
the clinical course in hypertensive patients. In these studies, diuretics or -blockers were the first 
choice in the treatment groups.1 These drugs were tested against placebo or “usual care” in the 
control groups. Later studies, published from 1995 onwards, have been summarized 
prospectively and a report has recently appeared in the Lancet.2 In many of these studies on the 
		
		 -blockers or diuretics, since, at that time, 
giving no treatment was considered un-ethical, even in patients with only moderate hypertension.  
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These data can be used to explore whether the ability to prevent various hypertension-related 
events differs for the various newer drugs. A prerequisite is that the drug effects in the control 
	 -blockers or diuretics are constant. Although one would expect absolute treatment 
effects to be related to the risk of morbidity in the population under study, the relative effects 
could be constant. 
We therefore examined the relationship between clinical outcome and basal risk level for 
various categories of events in studies on the traditional anti-hypertensives. To the extent that the 
relative drug effects could be considered constant, we drew conclusions from an overview of 
published data on the newer drugs. We used a Bayesian statistical approach, focusing on 
differences between the drug groups.  
 
Methods 
Our main question was whether there are different effects of treatments with ACE-inhibitors and 
calcium antagonists in patients with hypertension. We chose to study the effects on the 
occurrence of stroke, coronary disease and heart failure separately. We prepared an overview 
using a Bayesian fixed effect model similar to the one described in Aursnes et al 2000.3 For 
simulating from the distributions in the present paper we have used the program package 
WinBUGS available free of charge at http://www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml. The 
main difference was that, on that occasion, when studying patients with osteoporosis, we 
combined only four studies at a time, whereas we now brought together up to 27 studies. Some of 
the studies were quite small. Near homogeneity was obtained by doing calculations on relative 
effects only. Thus, as opposed to absolute effects, for instance differences in number of events 
per year in drug groups versus control groups, we used the corresponding ratio between the two. 
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We chose to always relate the drug effects to the number of events observed with placebo drugs. 
We could achieve this with our model, even when only about half the eligible studies included 
placebo-treated groups. Therefore all effect ratios (relative risks) reported are founded on all the 
studies, unless otherwise stated in Results. We excluded a few of the studies in our primary 
analysis, however, in order to further address the question of heterogeneity in the study material. 
For purposes of demonstration, we included results from all eligible studies in the calculations. 
 
Primary data 
Data were gathered from two sources. The first source was a meta-analysis of studies that have 
been published since 1995 on the effect of anti-hypertensive drugs on clinical outcomes.2 From 
that meta-analysis we selected studies on ACE-inhibitors and calcium antagonists tested against 



	


		
 -blockers. Among the various study 
endpoints recorded we chose the effects on stroke, coronary disease and heart failure. Other 
endpoints, like total death, will necessarily be a sum of the effects in all these categories. We 
found 14 eligible studies,4,5,6,7,8,9,10,11,12,13,14,15,16,17 of which two studies contained no data on heart 
failure.6,7 In four of the studies hypertension was not one of the inclusion criteria.4,5,6,7 Although 
many of the patients were hypertensive, the average blood pressures were 123-139/74-79  mmHg. 
We therefore excluded these studies in our primary analysis. The same applied to the CAPPP 
study.10  This was a randomized study on an ACE-inhibitor in hypertensive individuals, but the 
blood pressure levels were higher in the treatment group than in controls at the start of study, 
indicating faulty randomization.  
		

					
 -blockers 
were tested against no treatment. We chose studies including patients with diastolic blood 
pressures up to 115 mmHg. This was the inclusion criterion used by The Swedish Council on 
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Technology in Health Care, and a list of such studies was published in June 1994 with tables in 
English.1  Of the 14 studies listed there,18,19,20,21,22,23,24,25,26,27,28,29,30,31 one dealt with several drug 
groups31 and was omitted by us, whereas in the others diuretics was the first choice drug, often in 

 -blockers.  We used only strata I-II in the HDFP-study22 which fulfilled our 
inclusion criterion for blood pressure. We included all patients in EWPHE 26 although some 
patients had diastolic blood pressures up to 119, but others had pressures down to 90 mmHg. We 
observed that the meta-analysis by Collins et al,32 included another three studies not included by 
us. Among those, one did not include diuretics,33 one had methyldopa as an alternative first 
choice,34 and one accepted  only diastolic blood pressures above 110 mmHg at start of study.35 
We thus ended up with altogether 13 eligible studies in this group. Notably, none of these 
included data on heart failure.  
The mentioned meta-analysis published in 2000 included all studies published in 1995 and 
later.2 It did not i
				 -blockers were 
compared with no treatment. Since the Swedish report1 was published in 1995, we also searched 
Medline for the year 1994 to see whether any publications had been left out, but did not find any. 
 
The model 
Let us now consider one particular kind of drug and one specific endpoint. Assume that there are 
n studies on the effects of this kind of drug given this endpoint. When considering the effects of 
	 -blockers on stroke or coronary disease, n = 21. For i = 1,……,n let 
 
p1,i = the probability of at least one occurrence of the specific endpoint for an arbitrary patient in 
the course of the study period of the ith study when placebo is used 
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p2,i = the probability of at least one occurrence of the specific endpoint for an arbitrary patient in 
the course of the study period of the ith study when the particular kind of drug is used 
 
X1,i  = the number of patients with at least one occurrence of the specific endpoint in the course of 
the study period of the ith study when placebo is used 
 
X2,i  = the number of patients with at least one occurrence of the specific endpoint in the course of 
the study period of the ith study when the particular kind of drug is used 
 
m1,i = the number of patients in the ith study in the placebo group 
 
m2,i = the number of patients in the ith study in the particular drug group 
 
We assume X1,i  ~   Bin(m1,i , p1,i)  while X2,i  ~   Bin(m2,i , p2,i)  and that all variables are 
independent. Furthermore, we assume that the multiplic

 	

the particular kind of drug and the specific endpoint is constant in all n studies, regardless of 
prevalence and length of study period, i.e. 
  = p2,i / p1,i,          i=1,.....,n 
Therefore, in practice, we will have only n+1 free parameters p1,i   
  
Probability distributions describing our initial uncertainty are called prior distributions (that is, 
before the data are collected). Here we assume that the prior distributions for p1,i       i=1,.....,n and 



 !			

on p1,i,     i=1,.....,n and assuming that the effect of the particular kind of drug is at least as good 
as the effect of placebo. 
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" a b,  
 c the risk ratio corresponding respectively to  ACE-inhibitors, diuretics or 
-blockers and calcium antagonists. The risk ratio of ACE-	


		 a/c is 
then expressed by 
a/c a# c , 
and that of calcium antagonists to diur	 -	 c/b by 
  c/b c# b . 
We constructed the posterior probability distributions of the relative effects of ACE-inhibitors 
versus calcium antagonists with tree different endpoints: stroke, coronary disease and heart 
failure. We then calculated point estimates of effects with 95% credibility intervals. As an 
intermediate step in this procedure we obtained similar information on the effects of the three 
active groups of drugs, ACE-	


		
	 -blockers, tested 
against placebo.  
 
Further analysis 
For purposes of comparison, we also calculated the differences in effects of ACE-inhibitors and 
calcium antagonists by only using the results from the two studies that had compared these two 
drugs directly.17,8 For that purpose we used the same model as the one described above. 

			
				 -
blockers against placebo, we calculated basal annual risks in the various populations under study 
and plotted these against the effects reported in the same studies. We were able to do this both 
with stroke and with coronary disease as endpoint.  
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Results 
ACE-inhibitors and calcium antagonists have an almost identical ability to prevent stroke in 
hypertensive individuals (figure 1). This is the result of the full analysis showing a risk ratio (RR) 
of 1.04, and also of the calculation that included only the studies ABCD17 and STOP-28 
(RR=1.02) in which a direct comparison between these two drug groups was  performed. Notably 
the result of our calculation, including the credibility interval for the second ratio, is identical to 
the result obtained with a non-Bayesian method presented by others.2 When we include studies 
not directly aimed at hypertensive individuals and a study without proper randomization, the RR 
deviates from unity (figure 1). The same figure also shows that the three different drug groups all 
reduce the stroke risk by 37 to 45% relative to placebo. 
As opposed to the effect on stroke, the effects on the occurrence of coronary disease in patients 
with hypertension differ for the various drugs (figure 2). The effects are quite similar for ACE-
	
	 -blockers, a 22% and 18% reduction respectively, 
relative to placebo. Calcium antagonists reduce coronary disease by 9% only. When this 
difference between ACE-inhibitors and calcium antagonists was analysed using our Bayesian 
approach the outcome was a 14% difference, with a credibility interval reaching identity. Figure 
2 also shows that a direct comparison of ACE-inhibitors and calcium antagonists estimates the 
former group to be 19% more effective. When the studies HOPE4, PART25, QUIET6 and SCAT,7 
which are not hypertension studies were included, and even CAPPP13 with its faulty 
randomisation, the relative risk did not change substantially.  
$
		
			%
	 -blockers have a better 
effect than calcium antagonists do on the occurrence of coronary disease in hypertensives.  
Formally tested the risk ratio is 1.11, with a 95% credibility interval of 1.01 to 1.22. 
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The existing data on heart failure are collected in figure 3. All the tested drug groups have a 
profound preventive effect on the occurrence of heart failure when given to hypertensive patients, 
showing reductions of 44% to 56%. Using 11 out of the 14 studies listed in figure 3, the risk ratio 
of ACE-inhibitors against calcium antagonists is 0.79 with a credibility interval of 0.65 to 0.95. 
The ratio hardly changes when CAPPP is also included in the calculation, whereas the outcome 
did change when HOPE and PART2 were put together with the other studies.  
The far right-hand columns in figures 1 to 3 give the annual risk of events of various kinds in 

		&
	

	
%		 -
blockers tested against placebo to figure 4, where the calculated treatment effects for each of the 
studies are plotted against the annual risks in the control population. The plot shows that the 
approximately 40% risk reduction for stroke is fairly constant through all degrees of basal risk. 
On the contrary, the effect of the treatment on coronary disease is positively correlated with risk. 
When the annual risk of coronary disease exceeds 2%, the effect on coronary disease is 
comparable to the effect on stroke. In low risk hypertensives, on the other hand, drug treatment 
seems to have a deleterious effect on coronary disease. Notably, the figure also shows that in 
hypertensive individuals, or at least in those included in clinical trials, the risk of stroke is just as 
high as the risk of coronary disease, whereas in normotensive populations of similar age we know 
that coronary disease is far more prevalent than stroke.  
 
Discussion 
With all clinical evidence included, we found a 37-45% reduction in the risk of stroke when 
hypertensive individuals are treated with various groups of drugs. Thus, given this endpoint, no 
differences are observed between ACE-inhibitors, calcium antagonists and a combined group of 
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diuretics and beta-blockers. Since we used the combined group as a point of reference in our 
calculations, we assumed that differences in effects obtained within this group were determined 
by chance only. Fortunately, as seen from figure 4, the effects on stroke are constant across 
various levels of underlying risk in the population.  Notably, a similar conclusion as to 
differential effects can be drawn from the analysis including two studies only, see figure 1, which 
shows the same effect of ACE-inhibitors and calcium antagonists, a result almost identical to the 
one obtained from the calculation where 22 studies were included.  
 Our conclusions are much weaker when it comes to the effects on coronary disease. All the 
same, the conclusion from the combination of two studies (see figure 2) that the ACE-inhibitors 
are more efficacious than calcium antagonists, is supported by the full calculation with all studies 
included. So, despite the result shown in figure 4 that the effect of diuretics and beta-blockers is 
dependent on the underlying risk, this conclusion may be correct. One likely explanation is that 
other drug groups, if they had been tested directly against placebo, would show the same 
association with underlying risk. Indeed, in one instance such a test was performed. In the 
TOMHS study,31 various drug groups were tested against placebo in patients with particularly 
low risk. The treated fared less well than the untreated, but the number of events was too low to 
draw firm conclusions. All in all, we believe that the preventive effect of calcium antagonists on 
the risk of coronary disease is both statistically and clinically less than both the effect of ACE-
inhibitors and of diuretics or -blockers.  
$

					
		 -
blockers on heart failure vary more than can be put down to chance, which would invalidate our 
conclusion. With our fixed effect model it is assumed that this is not the case. Notably, all three 
drug groups had a profound beneficial effect on this outcome. There are some differences, 
however, and the conclusion of our analysis is a statistically significant difference between ACE-
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inhibitors and calcium antagonists, with consistent results from both the two and from the 14 
studies brought together.  
The clinical significance of our all over result is less clear, but it is easy to conclude, as others 
have done before, that stroke can be prevented effectively by using the less expensive diuretics 

 -blockers.36 Furthermore, there is no possibility to choose between ACE-inhibitors and 
calcium antagonists when a secondary drug is needed and prevention of stroke is in mind. 
A question mark is attached to coronary disease. It has been suggested that calcium 
antagonists are deleterious to patients with acute coronary occlusions, but the warning has usually 
referred to short-acting drugs of the dihydropyridine type. The studies included in our analysis 
referred mainly to long acting variants and were directed at the preventive effects of the drugs on 
manifestation of coronary disease. However, a modest reduction of 9% is observed for calcium 
antagonists relative to placebo, significantly less than for both ACE-inhi	
	 -
blockers. Together with the observation that hypertensive individuals with low risk of coronary 
disease become worse when treated, and because it is hard to tell which people host a beginning 
coronary sclerosis, a modest demand would be that calcium antagonists should be withdrawn 
from the first line armament of drugs for the mildest forms of hypertension.  
We think we have made interesting observations by successively excluding and including the 
HOPE study in our analysis. Since this is a large study dealing with an ACE-inhibitor it has a 
potentially large effect on the risk in the meta-analysis relative to calcium antagonists. The 
inclusion of this study, together with the PART 2 study which also included patients who were 
normotensive, diminished the difference between the two drug groups when the endpoint was 
heart failure. A likely explanation is that ACE-inhibitors prevent heart failure by lowering the 
blood pressure only. Other effects, like diminishing the size of infarctions, have also been 
suggested for this drug group.37 
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We do not know to what extent our fixed effect model holds true in respect of heart failure. 
This outcome will be important in an ongoing study,38 of which one arm already has been 
	
		
 -blocker, was linked to increased frequency of heart 
failure. Further results from this and other future studies will change our database. Fortunately, 
the Bayesian model can easily be updated when new data are forthcoming. In the meantime 
patients must be treated according to the best knowledge available so far. 
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